UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An analysis of genetic heterogeneity in untreated cancers

Nature reviews. Cancer, 2019-11, Vol.19 (11), p.639-650

2019

Volltextzugriff (PDF)

A Case of Recurrence of Fibrolamellar Hepatocellular Carcinoma After 18 Years Underscores the Need for Extended Patient Surveillance

Curēus (Palo Alto, CA), 2024-07

2024

Volltextzugriff (PDF)

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic

Cancer control, 2021-01, Vol.28, p.10732748211009945-10732748211009945

2021

Volltextzugriff (PDF)

Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy

The Journal of clinical investigation, 2021-08, Vol.131 (16)

2021

Volltextzugriff (PDF)

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Cancers, 2022-10, Vol.14 (21), p.5347

2022

Volltextzugriff (PDF)

DNA mismatch repair in cancer

Pharmacology & therapeutics (Oxford), 2018-09, Vol.189, p.45-62

2018

Volltextzugriff (PDF)

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

JCO precision oncology, 2022-06, Vol.6 (6), p.e2100510

2022

Volltextzugriff (PDF)

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

Clinical epigenetics, 2023-04, Vol.15 (1), p.74-74, Article 74

2023

Volltextzugriff (PDF)

897-B A DNAJB1-PRKACA fusion peptide vaccine combined with ipilimumab and nivolumab elicits polyclonal fusion-specific T cell responses in fibrolamellar carcinoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1820-A1820

2023

Volltextzugriff (PDF)

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: implications for clinical practice

Lung cancer (Amsterdam, Netherlands), 2016-05, Vol.95, p.82-87

2016

Volltextzugriff (PDF)

Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection

Oncoimmunology, 2021-01, Vol.10 (1), p.2001159-2001159

2021

Volltextzugriff (PDF)

641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A733-A734

2023

Volltextzugriff (PDF)

The role of epigenetic therapies in colorectal cancer

Current problems in cancer, 2018-11, Vol.42 (6), p.530-547

2018

Volltextzugriff (PDF)

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

Clinical and translational science, 2021-05, Vol.14 (3), p.954-963

2021

Volltextzugriff (PDF)

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-05, Vol.20 (3), p.428-437

2017

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic

Annals of surgery open, 2022-12, Vol.3 (4), p.e207-e207

2022

Volltextzugriff (PDF)

Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches

The cancer journal (Sudbury, Mass.), 2019-07, Vol.25 (4), p.287-295

2019

Volltextzugriff (PDF)

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Cancer cell, 2022-03, Vol.40 (3), p.252-254

2022

Volltextzugriff (PDF)

A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16217-e16217

2023

Volltextzugriff (PDF)

Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4117-4117

2024

Volltextzugriff (PDF)

A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS4197-TPS4197

2024

Volltextzugriff (PDF)

Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation

Mayo Clinic proceedings, 2021-05, Vol.96 (5), p.1374-1375

2021

Volltextzugriff (PDF)

Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.506-506

2024

Volltextzugriff (PDF)

Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS573-TPS573

2024

Volltextzugriff (PDF)

Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4091-4091

2023

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(52)
Berichte
(1)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

An analysis of genetic heterogeneity in untreated cancers

A Case of Recurrence of Fibrolamellar Hepatocellular Carcinoma After 18 Years Underscores the Need for Extended Patient Surveillance

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic

Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

DNA mismatch repair in cancer

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

897-B A DNAJB1-PRKACA fusion peptide vaccine combined with ipilimumab and nivolumab elicits polyclonal fusion-specific T cell responses in fibrolamellar carcinoma

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: implications for clinical practice

Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection

641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma

The role of epigenetic therapies in colorectal cancer

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer Clinic

Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches

Expanding the immunotherapy roadmap for hepatocellular carcinoma

A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma

Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging

A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma

Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation

Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma

Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy

Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade

Suchergebnisse filtern